(Johnson&Johnson) Johnson&Johnson announced total sales of $24.80 billion in the fourth quarter of 2021, up 10.4% from the prior year but below estimates of $25.29 billion.
In FY21, Johnson&Johnson posted sales of $93.8 billion, an increase of 13.6% from the prior year. The operational sales increase was reported at 12.2%.
Net earnings in the fourth quarter were reported at $4.736 billion, an increase of 172.5% from the prior year. FY21 net earnings were $20.878 billion, an increase of 41.9% from the prior year.
Fourth-quarter diluted earnings per share was reported at $1.77, up 172.3% from the prior year. FY21 diluted EPS was $7.81, up 41.7% from the prior year.
Johnson&Johnson said it expects Covid-19 vaccine sales in 2022 to rise to $3.5 billion, up from $2.39 billion in FY21, with the improved forecast reflecting an easing of manufacturing bottlenecks and rising demand.
The company expects its FY22 adjusted operational growth in sales to be 7.7%, with an operational EPS increase of 9.2%.
JNJ: NYSE is down -0.53% on premarket.
